{"disease":{"id":"aspergillosis","name":"Aspergillosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":8},"drugs":{"marketed":[{"drug_id":"isavuconazonium","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cresemba","generic_name":"ISAVUCONAZONIUM","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Azole Antifungal","quality_score":60,"revenue":null,"mechanism":"Isavuconazonium sulfate is a prodrug that converts to isavuconazole, an azole antifungal."},{"drug_id":"voriconazole","indication_name":"Invasive aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"voriconazole","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"caspofungin","indication_name":"Refractory Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cancidas","generic_name":"CASPOFUNGIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":63,"revenue":null,"mechanism":"Cancidas works by inhibiting the synthesis of beta-1,6-glucan, a critical component of the fungal cell wall."},{"drug_id":"isavuconazonium","indication_name":"Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cresemba","generic_name":"ISAVUCONAZONIUM","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Azole Antifungal","quality_score":60,"revenue":null,"mechanism":"Isavuconazonium sulfate is a prodrug that converts to isavuconazole, an azole antifungal."},{"drug_id":"itraconazole","indication_name":"Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Invasive pulmonary aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Invasive pulmonary aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Refractory Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Allergic bronchopulmonary aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Allergic bronchopulmonary aspergillosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":47,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05707156","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","phase":"","overall_status":"COMPLETED","enrollment_count":12032,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT02879305","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2964,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01386437","title":"Natural History of Individuals With Immune System Problems That Lead to Fungal Infections","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04935463","title":"Mucormycosis in COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":728,"lead_sponsor_name":"Montefiore Medical Center","has_results":false},{"nct_id":"NCT01782131","title":"A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06028451","title":"ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Southeast University, China","has_results":false},{"nct_id":"NCT07330986","title":"Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China","phase":"","overall_status":"COMPLETED","enrollment_count":542,"lead_sponsor_name":"Jianfeng Xie","has_results":false},{"nct_id":"NCT00412893","title":"Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":527,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT04232956","title":"Invasive Pulmonary Aspergillosis and Severe Influenza","phase":"","overall_status":"COMPLETED","enrollment_count":478,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07238114","title":"Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT03828773","title":"PTX3-targeted Antifungal Prophylaxis","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Bochud Pierre-Yves","has_results":false},{"nct_id":"NCT03443336","title":"Azole-resistance in Aspergillus","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT03827694","title":"Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Arkansas Children's Hospital Research Institute","has_results":false},{"nct_id":"NCT04530799","title":"Prospective Observational Trial of IAPA","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03349931","title":"Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT00036166","title":"Study of FK463 for the Treatment of Invasive Aspergillosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03121235","title":"PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.","phase":"","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04550936","title":"A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.","phase":"","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06382922","title":"Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Rome Tor Vergata","has_results":false},{"nct_id":"NCT06645210","title":"Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06069505","title":"Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Bart Rijnders","has_results":false},{"nct_id":"NCT07516158","title":"Vitamin D and Immune Response in Pulmonary Tuberculosis With and Without Chronic Pulmonary Aspergillosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT03391492","title":"Invasive Pulmonary Aspergillosis Complicating Influenza Infection","phase":"","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT07272915","title":"Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)","phase":"","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05671328","title":"Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia","phase":"","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT05065658","title":"Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"Medical University of Graz","has_results":true},{"nct_id":"NCT03059992","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT05101187","title":"Olorofim Aspergillus Infection Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":225,"lead_sponsor_name":"F2G Biotech GmbH","has_results":false},{"nct_id":"NCT04818853","title":"COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)","phase":"","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04431804","title":"THYME AND CARVACROLL Nanoparticle Effect on Fungi","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT03221075","title":"Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"University Hospital of Cologne","has_results":false},{"nct_id":"NCT05783544","title":"Impact of A. Lumbricoides on Pulmonary Aspergillosis Development","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT06440915","title":"Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT02104479","title":"Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Heidelberg University","has_results":false},{"nct_id":"NCT05045391","title":"Pulmonary Aspergillosis in Tuberculosis Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT07493629","title":"Immune Status and Disease Control of Inflammatory Airway Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Ningbo University","has_results":false},{"nct_id":"NCT06447402","title":"A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT02273661","title":"Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT03920527","title":"Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT05860387","title":"Early Diagnosis of Invasive Lung Aspergillosis","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University Hospital Ostrava","has_results":false},{"nct_id":"NCT00634049","title":"Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT07040332","title":"Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis","phase":"","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT06537726","title":"Breath Analysis for the Detection of Invasive Fungal Infections","phase":"","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT04824417","title":"A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT02180165","title":"Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06654076","title":"Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT02646800","title":"Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Astellas Pharma China, Inc.","has_results":false},{"nct_id":"NCT05444946","title":"Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT05037851","title":"A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Pulmocide Ltd","has_results":false},{"nct_id":"NCT04358419","title":"Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate","phase":"","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Inger Lise Gade","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}